| Date | Title | Description |
| 17.09.2026 | AstraZeneca зарегистрировала в России новый препарат от гипертензии | AstraZeneca зарегистрировала в России новый препарат от гипертензии
Минздрав зарегистрировал «Баксфенди» (МНН баксдростат) для лечения артериальной гипертензии. Препарат разработан AstraZeneca и относится к новому классу ингибиторов альдост... |
| 17.09.2026 | Dr. Alison Armour agrees to become Chief Medical Officer of Alpha Fusion, as Company Advances Integration of At-211 Businesses with Curadh MTR | — Combining Both Companies' Astatine At-211 Assets, Development Capabilities, and Supply Chains to Create a Global Targeted Alpha Therapy Company —
TOKYO, Sept. 17, 2026 /PRNewswire/ -- Alpha Fusion Inc. ("Alpha Fusion"), a clinic... |
| 04.09.2026 | Trump and Kennedy’s health industry deals haven’t been enforced and are at risk of vanishing | Getting your Trinity Audio player ready...
By Stephanie Armour, KFF Health News
In the thick of his competitive reelection race in Michigan, Republican Rep. Tom Barrett joined Health and Human Services Secretary Robert F. Kennedy Jr. at a s... |
| 01.09.2026 | SocialRx recognized as a 2026 Fierce 50 honoree | SocialRx has been named a Fierce 50 honoree for 2026
Atlanta-based SocialRx recognized by Fierce Healthcare for driving advancements in medicine, fostering innovation and shaping the future of and healthcare.
We know connection and communit... |
| 05.08.2026 | Icotyde Has Only 90 Days of Sales History When Cavanaugh Takes J&J’s Helm | By Benjamin Eddie
Published: Aug 05 2026, 12:52 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 05.08.2026 | Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journey | Expedition Therapeutics has secured an oversubscribed $115 million series B financing from a line-up of big-name investors to propel its lead DPP1 inhibitor through phase 2.
The round was led by General Atlantic, with fellow new investors R... |
| 02.08.2026 | AstraZeneca Targets $400B Bristol Myers Squibb Merger Twelve Years After Spurning Pfizer | By Joshua Mitchell
Published: Aug 02 2026, 5:39 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 27.07.2026 | AstraZeneca Q2 Earnings Beat Analysts as Cancer Drugs Carry $80B Target | By Jerry Owens
Published: Jul 27 2026, 10:32 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 16.07.2026 | Samsung Bioepis Grows Australia Biosimilar Portfolio to Four as PBS Default Reform Nears | By Henry Baker
Published: Jul 16 2026, 11:01 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 10.07.2026 | KKR-backed Allyntra debuts to serve medtech industry as it announces new CEO | Global investment giant KKR has launched Allyntra, a new precision-engineered solutions platform for the medtech industry, and announced several senior management changes.
The Allyntra debut is part of the investment firm’s strategy to supp... |
| 30.06.2026 | BMS-backed Beeline 'putting worker bee mentality into effect' with $126M series A extension | Just two and a half months after buzzing out of stealth with $300 million and five autoimmune programs from Bristol Myers Squibb, busy Beeline Medicines has flown an extra $126.3 million back to its hive.
The sweet series A extension comes ... |
| 23.06.2026 | Merck KGaA pledges $50M to build new cardio biotech with eye to later acquisition | Merck KGaA has committed $50 million to build a new biotech with prolific life science investor Versant Ventures, with the ultimate goal of devouring the NewCo down the line.
The new outfit, called Saturnus Bio, was announced today by Merck... |
| 18.06.2026 | cAMPfield harvests $180M series A to advance oral IBD drug licensed from Newsoara | In another biotech born out of China’s “NewCo” model, cAMPfield Therapeutics has launched with a $180 million series A and a focus on oral medicines for inflammatory diseases.
The San Diego-based company boasts a star-studded investor list,... |
| 16.06.2026 | How Biogen is transforming its pipeline with a VC mindset and an ‘entrepreneurial spirit’ | From persevering with a tricky Alzheimer’s program to securing a late-stage CD38-directed antibody and posting encouraging lupus data, Biogen has remained in the news recently—and that’s no accident.
The neurology- and immunology-focused bi... |
| 12.06.2026 | Pentagon Bans Alibaba, Baidu, BYD From Defense Contracts June 30: 188 Chinese Firms Now Designated | By Shannon Harwood
Published: Jun 12 2026, 06:52 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 11.06.2026 | FDA Approves First Oral COVID-19 Post-Exposure Pill, Cuts Household Infection Risk 67% | By John Bright
Published: Jun 11 2026, 14:47 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 20.05.2026 | With $30M launch, Oorja Bio breathes new life into South Korean fibrosis candidate | In the sprawling metropolis of Houston, a new biotech has emerged to tackle the biology underlying a lung disease that has no clear cause. Oorja Bio launched yesterday afternoon with $30 million and an in-licensed, novel approach to treat i... |
| 14.05.2026 | Create Medicines fashions $122M fundraise for in vivo CAR-T dreams | As the wave of in vivo CAR-T hype crests, Create Medicines is catching the swell with a $122 million series B meant to back its early pipeline of autoimmune and cancer candidates.
Originally launched in 2021 as Myeloid Therapeutics by cell ... |
| 21.04.2026 | Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia | A pair of Sage Therapeutics veterans has launched a neurology-focused startup armed with $106 million and a clinical-stage pipeline of assets licensed from Eisai and Hansoh Pharmaceutical.
Heading up the pipeline for the newly launched Tort... |
| 16.04.2026 | Early-stage funding slumps toward post-pandemic low, piling more pressure on biotech startups | A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing the already limited funding opportunities available for startups.
The data come from J.P. Morgan’s first-quarter b... |
| 15.04.2026 | Bain-backed Beeline Medicines buzzes out of stealth with $300M and 5 programs from BMS | The former leaders of SpringWorks Therapeutics are back with a new biotech venture that is already buzzing from a $300 million series A.
Beeline Medicines flew out of stealth today with its stores already filled by an investment team led by... |
| 27.03.2026 | 'We need to put some bad ideas to bed': Inside Incubate's battles for biotech on Capitol Hill | Incubate Founder and Executive Director John Stanford spent a busy day on Capitol Hill this week making the case that the success of the domestic biotech industry is an issue of national security, health care access and economic competitive... |
| 26.03.2026 | OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline | Oral peptide specialist Pinnacle Medicines has secured an $89 million series B with backing from investors in the U.S. and China, bringing the company’s total fundraising haul to $134 million.
OrbiMed, which has backed Pinnacle since its in... |
| 19.03.2026 | Moon Rabbit Appoints Loren Levinson EVP, Executive Strategy Director | Leadership addition expands agency's strategy capabilities amid continued growth
NEW YORK, March 19, 2026 /PRNewswire-PRWeb/ -- Moon Rabbit, an independent advertising and marketing agency focused on pharma and healthcare, today announced t... |
| 17.03.2026 | R1 zooms out of stealth with $77.5M series A to advance chronic kidney disease treatment | R1 Therapeutics is debuting with an oversubscribed $77.5 million series A financing aimed at advancing its first-in-class therapy for chronic kidney disease (CKD) patients on dialysis with high phosphate levels.
The funding was co-led by Ab... |
| 12.03.2026 | Novo Holdings sees assets shrink by a 3rd in wake of Novo Nordisk's nosediving share price | Novo Holdings saw its assets shrink by a third last year as part of the fallout of Novo Nordisk’s nosediving share price.
The Copenhagen-based firm, which is the controlling shareholder of Novo Nordisk, oversaw total assets of 694 billion D... |
| 10.03.2026 | Breakout Ventures launches $114M AI-focused fund | San Francisco venture capital firm Breakout Ventures announced the close of a $114 million fund to support founder-led companies working at the nexus of science and artificial intelligence.
Breakout’s Fund III brings together new investors ... |
| 05.03.2026 | VC firm to open 30K-square-foot biotech incubator in Salt Lake City | Venture capital firm Portal Innovations is planning to open a 30,000-square-foot science incubator in Salt Lake City while also establishing a venture fund to support early-stage life sciences and biotech companies.
The expansion is part of... |
| 18.02.2026 | Korsana crosses into crowded Alzheimer's field with $175M and anti-amyloid antibody | A new entrant in the race to shepherd antibodies for Alzheimer’s disease across the blood-brain barrier has emerged. Korsana Biosciences has catapulted out of stealth with $175 million and designs for a 2027 clinical debut.
The newly disclo... |
| 16.02.2026 | Biopharma funding to experience 'continued, albeit disciplined' recovery in 2026: PitchBook | Just as a disciplined a soccer player might pass on a hopeful shot in favor of a better chance later on, the biopharma venture capital market reflected a preference for de-risked assts over platforms and is expected to display a “continued,... |
| 12.02.2026 | European VCs join forces to boost flagging biotech investment in the region | Heavyweight European venture capital firms like Novo Holdings and Sofinnova Partners have joined together to make the case for more urgently needed funding in the continent's biotech ecosystem.
The European Life Sciences Coalition (ELSC), w... |
| 03.02.2026 | OS Therapies Initiates FDA BLA Filing for OST-HER2 to Prevent or Delay Recurrent Pulmonary Metastatic Osteosarcoma | At FDA's request, Type D Meeting expected in March 2026 to review Comparative Oncology biomarker data from patients treated in OST-HER2 Phase 2b human clinical trial and OST-HER2 trial in spontaneous osteosarcoma in canines
Company remains ... |
| 22.01.2026 | Corxel secures $287M series D to fund phase 2/3 obesity studies of oral GLP-1 drug | In a reminder of the money still on the table for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in series D funds to bankroll phase 2 studies of its oral GLP-1 receptor agonist.
Shanghai-headquartered Corxel licens... |
| 11.01.2026 | Parabilis Medicines Secures $305 Million for Cancer Drug Revolution | Parabilis Medicines recently closed an oversubscribed $305 million Series F financing round. This substantial capital propels its lead cancer candidate, zolucatetide, towards pivotal clinical trials for desmoid tumors and other challenging ... |
| 09.01.2026 | AirNexis takes flight with $200M, links up with China pharma for COPD asset in $955M biobucks deal | AirNexis Therapeutics is taking flight with $200 million and a clinical-stage asset from a Chinese pharma that aims to treat lung disease.
Founded by investment firm Frazier Life Sciences, new biotech AirNexis has connected with Haisco Phar... |
| 08.01.2026 | Parabilis rockets ahead with $305M series F to 'upend the status quo' with tumor drug | Parabilis Medicines is taking an early lead in the 2026 biotech fundraising race, closing a $305 million series F round that will fuel a pivotal push for its potential first-in-class cancer drug.
The funds come from a smorgasbord of existin... |
| 08.01.2026 | Innovation isn't enough: Biopharma needs urgent reinvention, PwC says | Attempting to scry the future of the pharmaceutical industry, professional services juggernaut PwC has laid out lofty ambitions for what it believes drugmakers could achieve by 2035—as well as the steps those companies should take in 2026 t... |
| 18.12.2025 | Karuna head, Teva alums meet minds to launch schizophrenia-focused biotech Syremis with $165M series A | A new mental health-driven biotech has arrived in Syremis Therapeutics. Co-founded by the mind behind Karuna Therapeutics and its novel schizophrenia treatment Cobenfy, the company has officially launched its mission to advance innovative t... |
| 01.12.2025 | EU teams up with Angelini to funnel €150M to European health startups | The EU has launched a new funding initiative to support healthcare startups across the continent. The EU’s investment arm, the European Investment Bank (EIB), is teaming up with Italian conglomerate Angelini Industries to funnel 150 million... |
| 01.12.2025 | Protego plans pivotal trial for AL amyloidosis prospect with $130M series B | Protego Biopharma is gearing up to bring its amyloid light-chain (AL) amyloidosis prospect into pivotal testing using its new $130 million series B fundraise.
The oversubscribed funding round, led by Novartis Venture Fund and Forbion, picke... |
| 24.11.2025 | 'People are getting used to it': Global uncertainties can't dampen upbeat Jefferies conference | The November storm clouds may have parted above the Jefferies Global Healthcare Conference in London last week, but market volatility, tariffs and a slowly dethawing IPO market continued to cast long shadows.
Still, no matter who Fierce cou... |
| 15.10.2025 | Arthrosi Secures $153 Million to Accelerate Gout Treatment | Arthrosi Therapeutics recently closed a significant $153 million Series E funding round. This vital capital directly supports late-stage clinical development of pozdeutinurad, a promising next-generation URAT1 inhibitor. The San Diego-based... |
| 15.10.2025 | Pelage Pharma raises $120M series B to untangle roots of hair loss with regenerative med | The latest strand in Pelage Pharmaceuticals’ growing funds comes from a $120 million series B fundraising round that the biotech plans to apply to its regenerative hair loss treatment.
Arch Venture Partners and Google Ventures co-led the fu... |
| 09.10.2025 | Expedition resupplies for phase 2 COPD voyage with $165M series A | Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding will fuel the Bay Area biotech’s DPP1 inhibitor EXPD-101 as it ventures into a study in patients with chronic obstruct... |
| 08.10.2025 | Arthrosi raises $153M, fueling dash toward phase 3 gout data in 2026 | Arthrosi Therapeutics has raised $153 million to bankroll its bid to clout gout. The series E financing gives the biotech the financial firepower to deliver data from two phase 3 trials next year.
San Diego-based Arthrosi completed enrollme... |
| 22.09.2025 | Big Pharma-backed MapLight plots IPO to advance neuro pipeline | MapLight Therapeutics has illuminated a path toward an initial public offering, filing with the Securities and Exchange Commission (SEC) on Sept. 19 to be listed on the Nasdaq under the ticker symbol "MPLT."
Should the IPO go thro... |
| 17.09.2025 | Eye disease biotech launches with $100M and sights set on Roche showdown | During his tenure at Roche's Genentech, ophthalmologist Jason Ehrlich, M.D., Ph.D., supported the development of the blockbuster eye disease med Vabysmo (faricimab). Now, as the co-founder and CEO of newly launched Ollin Biosciences, Ehrlic... |
| 17.09.2025 | VC Aditum launches cardiovascular biotech, offers Mabwell up to $1B for siRNA asset | California VC firm Aditum Bio is at it again, this time partnering up with China-based Mabwell Bioscience to launch a new biotech focused on cardiovascular disease.
Aditum has paid Mabwell $12 million in upfront and near-term payments for e... |
| 09.09.2025 | Trump signs memo to crack down on direct-to-consumer pharma ads | President Donald Trump signed a memorandum that aims to crack down on direct-to-consumer prescription drug ads, in a move that stops short of an outright ban.
The Trump administration will send out around 100 cease-and-desist enforcement le... |
| 13.08.2025 | VC firm Hatteras reels in $200M across 2 funds for early-stage life sciences investments | Hatteras Venture Partners has secured over $200 million across a pair of funds that are set to benefit up-and-coming biotechs alongside medtech and healthcare companies.
The money is spread across two funds—Hatteras’ seventh venture fund an... |
| 07.08.2025 | Artbio Secures $132M to Accelerate Precision Cancer Therapies | Artbio, a pioneering radiopharmaceutical firm, locked in $132 million Series B funding. This investment drives AB001, its innovative alpha radioligand therapy for metastatic castration-resistant prostate cancer, toward Phase II clinical tri... |
| 31.07.2025 | Frazier Life Sciences raises $1.3B for latest early-stage biotech venture fund | Frazier Life Sciences has gathered an impressive $1.3 billion in capital commitments for its 12th venture fund aimed at private early-stage biotechs.
The Palo Alto-based firm said it has now raised more than $3.6 billion across five dedicat... |
| 29.07.2025 | Radiopharma-focused Artbio paints path to clinic with $132M series B | Radiopharmaceuticals-focused Artbio has drawn in a $132 million series B to push its lead prostate cancer prospect through phase 2 trials and bolster its supply chain.
The round was co-led by Sofinnova Investments and B Capital, both new in... |
| 10.07.2025 | Radiopharma biotech raises $99M series B to test copper-based diagnostic, therapeutic combo | Nuclidium has raised 79 million Swiss francs ($99 million) as the Swiss and German biotech looks to continue the clinical journey of its copper-based radiopharmaceutical diagnostic and therapeutic offering.
The series B round was led by a q... |
| 20.06.2025 | Syncona blames 'challenging' market for shift in biotech investment strategy | Life sciences investment firm Syncona has blamed the “particularly challenging” market conditions for shifting its strategy away from early-stage biotechs and focusing on companies likely to offer near-term rewards.
The London-based firm’s ... |
| 18.06.2025 | Taxes, tariffs and interest rates hold key to biotech's future amid uncertain outlook: EY | Against an increasingly uncertain market backdrop, industry analysts EY said they are keeping an eye on potential pharmaceutical tariffs, tax rates and any drop in interest rates as key signposts for the sector's health.
With these variable... |
| 10.06.2025 | Questex Recognised for Content and Data-Driven Marketing Solutions | Questex, the leading information and event services company focused on the experience economy, announces it has been recognized for its impactful content and innovative data-driven marketing solutions from the Jesse H. Neal Awards, the Amer... |
| 24.05.2025 | Pharmacists stockpile most common drugs on chance of targeted Trump tariffs | Squeezed by insurers and middlemen, independent pharmacists such as Jolley find themselves on the front lines of a tariff storm. Nearly everyone down the line — drugmakers, pharmacies, wholesalers, and middlemen — opposes most tariffs.
Slas... |
| 20.05.2025 | SV Health’s latest pharma-backed dementia fund raises $269M to invest in new therapies | A dementia-focused transatlantic venture capital initiative has secured $269 million in commitments for its second fund.
The first Dementia Discovery Fund (DDF) was launched by VC firm SV Health Investors a decade ago with the goal of deliv... |
| 16.05.2025 | The Glyphosate Gamble: Georgia's New Law and the Future of Agriculture | In a bold move, Georgia has become the second state in the U.S. to shield Bayer, the maker of Roundup, from certain cancer claims. This law, set to take effect on January 1, 2026, is a double-edged sword. It aims to protect farmers and the ... |
| 15.05.2025 | Denmark’s economy boomed on drug exports — Trump’s tariffs threat won’t be what slows it down | Denmark’s economic growth, which was driven by what economists described as an “exceptional surge” in pharmaceutical exports, is expected to weaken this year.
The looming threat of U.S. tariffs on the pharma industry won’t be much of a fact... |
| 13.05.2025 | Dutch biotech Azafaros gains €132M series B to fund phase 3 trials of brain-penetrant drug | Azafaros has secured 132 million euros ($147 million) in series B funds that the Dutch biotech will use to push its rare neurological disease drug through two late-stage trials.
The candidate in question is nizubaglustat, a brain-penetrant ... |
| 07.05.2025 | Vivo Capital secures $740M to invest in preclinical- and clinical-stage biotechs | California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical- and clinical-stage life sciences companies.
The Vivo Opportunity Fund is an evergreen public fund that runs in three-year investment... |
| 18.04.2025 | 'America-first resurgence': Amid market correction, biotech nears new era, PitchBook says | Biotechs will need to be strategic to achieve “tariff-era success” as the sector enters an “America-first resurgence,” according to a new report from PitchBook. Companies focused on AI integration and manufacturing innovation are expected t... |
| 18.03.2025 | Arbor sails into rocky gene editing waters with $74M for rare liver disease therapy | As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead liver-targeting gene therapy into human trials.
The series C was led by Arch Venture Partners and TCGX, with new investors ... |
| 17.03.2025 | Latigo saddles up with $150M to spur non-opioid pain drugs through the clinic | Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid pain management drugs.
The round was led by Blue Owl Capital, with other participants including Deep Track Capital, Ac... |
| 20.12.2024 | Aadi pulls commercial-to-preclinical pivot, buying ADCs and selling approved drug to reboot business | Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading its approved product and licensing antibody-drug conjugates (ADCs) for $44 million upfront.
The Los Angeles-based ... |
| 19.12.2024 | The Shifting Sands of Pharma and Energy: Opportunities Amidst Uncertainty | In the world of finance, change is the only constant. Two sectors currently in the spotlight are pharmaceuticals and energy. Both face unique challenges and opportunities. Investors must navigate these shifting sands carefully.
Novo Nordisk... |
| 19.12.2024 | Former Seagen CEO's biotech raises $140M series A to ready PD1/VEGFR2 antibody for clinic | Two months after former Seagen CEO David Epstein unveiled his new project, the biotech has secured "over" $140 million in series A funds to push forward its potential Keytruda contender.
Ottimo was born in 2020 out of a collaborat... |
| 18.12.2024 | Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease. |
Recent sales of a little-known stock, Madrigal Pharmaceuticals (NASDAQ: MDGL), could bode well for Novo Nordisk A/S (NYSE: NVO). The pharma industry giant has seen explosive sales growth for its GLP-1 agonist drug, semaglutide. Marketed th... |
| 13.11.2024 | DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare Distribution | DKSH Healthcare and Euris have launched "ConnectPlus", a complete Customer Relationship Management (CRM) and Multi-Channel Engagement (MCE) platform set to transform healthcare distribution across APAC. This data-driven, agile sol... |
| 13.11.2024 | Keurig Dr Pepper taps new CMO to accelerate digital-first marketing | Listen to the article 3 min
This audio is auto-generated. Please let us know if you have feedback.
Keurig Dr Pepper has appointed Drew Panayiotou as CMO of U.S. refreshment beverages, effective immediately, according to a press release. The... |
| 12.11.2024 | Novo Holdings, OrbiMed, Jeito lead $181M fundraise for ADC biotech | Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two antibody-drug conjugates (ADCs).
Healthcare investor OrbiMed led the oversubscribed series D financing, with Novo Nordi... |
| 21.10.2024 | Seaport loads up $225M series B to continue Karuna veterans' voyage to clinical milestones | After launching on its maiden voyage in April, Seaport Therapeutics and its crew of Karuna veterans have loaded up with $225 million in series B funds to support the journey to key clinical milestones for its neuropsychiatric medicines.
Sea... |
| 15.10.2024 | New cell therapy biotech emerges with $17M, thymus-targeting therapies | Cell therapy biotech Tolerance Bio has unveiled with $17.2 million and a mission of targeting immune diseases by stretching and saving the function of a key organ.
The Philadelphia biotech’s seed financing was led by Columbus Venture Partne... |
| 14.10.2024 | Fastenal and Eli Lilly: Two Titans of Industry on the Rise | In the world of stocks, two companies are making waves: Fastenal and Eli Lilly. Each stands tall in its respective field, showcasing resilience and innovation. Fastenal, a giant in inventory management, is poised to reclaim its all-time hig... |
| 13.10.2024 | Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top Eli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there. |
In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company in the world. It took that mantle from the long-held dominance by Johnson and Johnson (NYSE: JNJ) back in May of 2... |
| 07.10.2024 | Judo kickstarts with $100M to develop genetic medicines that strike out kidney disease | Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting the kidney.
Instructing Judo is CEO Rajiv Patni, M.D., an industry vet who most recently served as chief R&D off... |
| 31.07.2024 | A New Dawn for Alzheimer's Treatment: The Promise of GLP-1 Drugs | In the realm of Alzheimer's research, a new player has emerged, and it’s wearing the familiar coat of a diabetes medication. Liraglutide, a glucagon-like peptide-1 (GLP-1) agonist, has shown potential in slowing cognitive decline, igniting ... |
| 30.07.2024 | Novo's Victoza Drug For Diabetes Shows Promise in Alzheimer's Treatment, But Misses Primary Goal | By Joseph Henry
Published Jul 30, 2024 9:09AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard Share on Pocket
Novo Nordisk's Victoza, a popular diabetes medication, has shown mixed results in a mi... |
| 16.07.2024 | Novo Holdings, J&J-backed Asceneuron raises $100M to take Alzheimer's asset into phase 2 | With the first wave of Alzheimer’s disease drugs reaching the market, investors continue to seek out the next big advance in this red-hot area of neuroscience R&D.
For Novo Holdings, the controlling shareholder of Novo Nordisk, this has... |
| 20.06.2024 | Biopharma dealmaking continues to rise, but M&A values hold steady: PwC | Thanks to a flurry of dealmaking across the Christmas period and into the new year, it sure feels like both biotechs and Big Pharma have picked up the pace when it comes to hunting down fresh assets. After crunching the data, PwC has come t... |
| 07.06.2024 | Top 2 dividend stocks to buy for long-term gains | Dividend stocks benefit from falling interest rates as money managers shift to income-oriented equities with yields above the S&P 500.
With signs of a cooling U.S. labor market, economy, and core inflation, the Federal Reserve may cut r... |
| 31.05.2024 | Moderna's RSV vaccine for older adults approved | figcaption>span]:font-sans">
Moderna's RSV shot for adults 60 and older was approved by the Food and Drug Administration on Friday, joining a growing group of vaccines protecting against the major respiratory threat.
Why it matte... |
| 03.04.2024 | Diagonal launches with $128M and a platform slanted toward agonist antibodies | Diagonal Therapeutics is taking shape, launching with $128 million and backed by the likes of BVF Partners, Atlas Venture and RA Capital to develop a pipeline of antibody agonists.
The company will use this significant financial firepower t... |
| 27.03.2024 | Unable to find a partner for stem cell therapy, Gamida accepts sale to investment firm to survive | With the search for a partner for an approved stem cell therapy coming up short, cash-strapped Gamida Cell has accepted that the only way to remain a going concern is to allow its principal lender to acquire the company.
The agreement will ... |
| 25.03.2024 | Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome | TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating
Prader Willi syndrome is the most common genetic cause of life-threatening childhood obesity
... |
| 15.03.2024 | Health | Why COVID patients who could most benefit from Paxlovid still aren’t getting it | Arthur Allen | KFF Health News (TNS)
Evangelical minister Eddie Hyatt believes in the healing power of prayer but “also the medical approach.” So on a February evening a week before scheduled prostate surgery, he had his sore throat checked... |
| 29.02.2024 | With seeds from Turning Point, a new biotech blooms with $100M to take on small molecules | The first signs of spring are beginning to emerge and so too are the shoots of the next biotech from drug designer J. Jean Cui, Ph.D.
BlossomHill Therapeutics has raised $100 million in a series B financing, bringing the company’s total fun... |
| 23.02.2024 | The Triangle's biotech growth has skyrocketed in the past decade | Data: CBRE; Chart: Axios Visuals
In less than a decade, the Triangle's biotech industry has more than doubled its lab space and added tens of thousands of new workers, as the region's profile among investors and companies soars.
The big pic... |
| 22.02.2024 | Frontier CEO weathers 'one of the hardest financings' of his career to close $80M series C | Frontier Medicines has just closed a $80 million fundraising, but, according to CEO Chris Varma, Ph.D., corralling the capital was, in his own words, harder than the bleakest days of the Great Recession.
“I've been either an investor or an ... |
| 21.02.2024 | It’s a mistake to assume Elon Musk is lying all the time—but his Neuralink comment needs verification | So, what to make of that Elon Musk comment earlier this week about Neuralink’s first patient seemingly recovering well and being able to control a mouse via his brain implant?
Let me start with a kind of defense of Musk: I think some people... |
| 13.02.2024 | Capitalizing on ADC frenzy, ProfoundBio attracts $112M oversubscribed series B | With Big Pharmas heading into 2024 with a renewed interest in antibody-drug conjugates (ADCs), it’s no surprise that ProfoundBio managed to assemble a who’s who of biotech investors for an oversubscribed series B round.
The likes of Lilly A... |
| 29.01.2024 | 23andMe breach targeted Chinese, Jewish populations | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hey there. Today, we discuss how Medicaid might pay for the costly but potentially curative sickle cell gene therapi... |
| 19.01.2024 | The Senate health committee looks into its first subpoena in 40 years | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
We’re seeing some rays of hope that this ghastly biotech job market may loosen up a bit. Also, Bernie Sanders wants ... |
| 16.01.2024 | The four biotech stories you need to read this morning | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! Hope you had a restful and reflective long weekend. Today, we talk a lot about regulatory policy — for flu va... |
| 09.01.2024 | JPM24, Day 2: GSK, Eli Lilly, Blueprint, SR One and more | Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2024 in San Francisco. Yesterday "Merger Monday" lived up to its name with deals for Novartis, J&J and Merck, and today, we’re also starting Tuesday with an early deal.... |
| 08.01.2024 | JPM24 opens with ADCs the hottest ticket in San Francisco | The overall deal flow in biopharma tapered off in 2023 but the big companies sure know what they want (what they really, really want), according to a new report from J.P. Morgan.
And that’s antibody-drug conjugates, which drove a fourth-qua... |
| 08.01.2024 | Biopharma M&A ripens as JPM launches | The JPMorgan Health Care Conference — the definitive launchpad for industry dealmaking — kicked off Monday.
Why it matters: As interest rates stabilize and the funding market for biotech rebounds, there will be plenty of white space in phar... |
| 29.12.2023 | There’s a less intimidating alternative to EpiPens for dangerous allergic reactions. Why won’t the FDA approve it? | My son Thomas has carried around a needle since he entered kindergarten at the age of 5. That was a big responsibility for a small child to carry an injector loaded with lifesaving epinephrine, but since he was 19 months old, he has worked ... |
